Search fresh public links, source activity, and post angles for Oncology Platform.
Fresh curated links around Oncology Platform are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Oncology Anonymous (not verified) Tue, 05/19/2026 - 08:34 field_thread_url https://cafepharma.com/boards/threads/oncology.709375/ board...
Solid Tumor Oncology Leadership Anonymous (not verified) Mon, 04/13/2026 - 05:05 field_thread_url https://cafepharma.com/boards/threads/solid-tumor-oncolog...
AbbVie Oncology Anonymous (not verified) Tue, 04/07/2026 - 20:01 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...
What You Should Know Greatly Health raised a $4 million seed round co-led by Pear VC and Commonweal Ventures to bring integrative oncology to a broader patient population. The comp...
What You Should Know Oncology AI innovator Triomics has announced a $22M Series B financing round led by Battery Ventures, pushing its total venture funding past $36 million. The e...
Nanotechnology is revolutionizing the landscape of cancer therapy, heralding a new era of precision oncology that extends far beyond traditional drug delivery systems. A recent spe...
Using this new platform, researchers developed a covalent antagonist targeting PD-L1, termed IB101, which was found to form a defined binding pocket that precisely positions the ac...
Oncology WW VP Anonymous (not verified) Thu, 05/28/2026 - 11:40 field_thread_url https://cafepharma.com/boards/threads/oncology-ww-vp.715506/...
A new high-throughput platform screens dozens of nanoparticle designs in living systems to identify those that reach tumor mitochondria, enabling more precise and effective cancer...
What You Should Know CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cance...
As radiopharmaceuticals continue to evolve, the convergence of scientific innovation, operational practicality, and clinical expertise is opening new possibilities in oncology. Th...
The companies have agreed to partner on next-generation radiopharmaceutical therapies aimed at up-to-eight solid tumor targets from Regeneron’s portfolio of antibodies, generated f...
Path-IO accurately stratified immunotherapy outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The model is validated across international real-world cohorts...
Today’s organoid companies underscore proof points in the ability to model complex human biology with high fidelity. At the same time, the government’s evolving regulatory stance i...
What You Should Know Patients with metastatic breast cancer and non-small cell lung cancer (mNSCLC) treated in independent community oncology practices lived longer than national b...
Domain-adaptive foundation model bridges clinical and preclinical cancer biology across 130,000+ oncology samples
Massachusetts biotech Nuvalent is turning to Guardant Health to develop companion diagnostics for its targeted cancer drugs, signing a multi-year deal to tap into Guardant’s “Infin...
Why biomarker-driven oncology trials require new thinking across patient recruitment, assay development and regulatory strategy.
A team at the Research Institute of the McGill University Health Centre (RI-MUHC) developed Opal into a well-known patient information platform that was used by thousands of patien...
Discover how biomarker strategies are transforming oncology trials and accelerating precision medicine breakthroughs.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.